In most patients, both adults and children, who have a new diagnosis of asthma and whose symptoms are mild but persistent, treatment with inhaled corticosteroids (ICS) should be recommended as soon as the diagnosis is made. This is a cost -effective and safe treatment. Patients should be cautioned that their asthma will not be cured with short -term treatment and that their symptoms may recur and their lung function may decline again if treatment is discontinued. If patients are reluctant to use ICS daily for long periods of time, it would be reasonable to delay the onset of treatment with ICS. They could subsequently be managed with intermittent therapy with either ICS or in combination with other medications, such as long -acting β-agonists. Initial therapy with leukotriene receptor antagonist is not likely to be as effective as initial therapy with ICS. Since treatment adjustments based on eosinophil counts in sputum can reliably predict short -term responses to corticosteroids and help identify the appropriate add -on therapy, it may be useful to use this measurement, when available, to guide inter mittent therapy.
INTRODUCTION
Inhaled corticosteroids (ICS) are the most effective anti inflammatory drugs in the management of asthma [1] . They control airway inflammation, particularly eosinophilic inflam mation [2] , improve airway calibre and airway hyperrespon siveness [3] , protect the airway against bronchoconstrictor stimuli such as exercise [4] and allergen [5] and prevent asth ma exacerbations [6] . These effects improve symptoms and quality of life, and decrease morbidity and asthma related mortality [7] . Despite more than 25 years of experience with these drugs, there are lingering doubts whether they are nec essary for patients with mild asthma as soon as they are diag nosed and whether they need to be taken continuously and whether they alter the natural history of asthma, particularly in children. This commentary examines the evidence provid ed for early inter vention in The Inhaled Steroid Treatment as Regular Therapy in Early Asthma (START) study and discuss es other recent publications that investigated whether regular therapy with ICS modifies the natural history of asthma.
Early inter vention (START study)
Most guidelines recommend a step wise approach to asth ma therapy, starting with short acting β 2 agonists for symp tomatic relief and using ICS when the asthma is mildly un controlled. However, since even the mildest form of asthma is associated with airway inflammatory changes, it seems rea sonable to start treatment with ICS as soon as asthma is di agnosed. The most comprehensive study of early inter vention with ICS is a 2 stage, multi center study [8, 9] of 103 patients with asthma diagnosed less than 12 months previously. Pa tients treated with budesonide 600 μg bid showed a rapid and significant increase in peak expiratory flow (PEF), which was maintained throughout the 2 year study period compared to the terbutaline treated patients. Their PEF was well main tained for a further year when they were switched to a low er dose of budesonide. However, patients who were switched from placebo to budesonide showed a significant improve ment in lung function, but, at the end of the year, their lung function was still significantly lower than that in patients who had received budesonide from the start of the study. Fur ther, the increase in PEF in patients in whom the introduction of budesonide was delayed for 2 years was consistently about half that seen in patients receiving budesonide from the start of the study.
This benefit was confirmed in the recently published START study [10] . This is one of the largest asthma studies ever con ducted. 7241 patients aged 5 to 66 years with mild persis tent asthma of less than 2 years duration were enrolled. Pa tients were randomized to low dose budesonide (400 μg once daily for adults and 200 μg once daily for children) or place bo in addition to their usual therapy for 3 years. At the end of this period, all patients received budesonide (open label)
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through additional treatment with long acting bronchodila tors (long acting β 2 agonists). This may not be an option for young children in whom these drugs are not recommended for use. For adult subjects, the choice of initial therapy may depend on individual preferences and values. Thus some pa tients may prefer to use ICS inter mittently.
Regular vs. inter mittent therapy (IMPACT study)
The efficacy of inter mittent treatment with ICS was investi gated in patients with mild persistent asthma over a one year period in a clinical trial conducted by the Asthma Clinical Re search Network supported by the US National Heart Lung and Blood Institute [15] . In a double blind trial, 225 adults were randomized to daily budesonide (200 μg twice daily), oral zafirlukast, or placebo. All participants were provided with a symptom based action plan of ICS therapy. The prima ry outcome was morning PEF averaged over 2 week periods of time. Secondary outcomes included FEV 1 before and after bronchodilator, frequency of exacerbations, degree of asthma control by questionnaire, the number of symptom free days, and quality of life. Although the placebo group (intermittent ICS alone) took budesonide for an average of only 0.5 week total during the study, there was no difference in PEF between groups after one year. However, daily budesonide therapy pro duced improved pre bronchodilator FEV 1 , reduced airway hy perresponsiveness, fewer sputum eosinophils, reduced exhaled nitric oxide, and improved symptoms compared to inter mittent therapy with or without zafirlukast. There was no dif ference between groups in post bronchodilator FEV 1 , but one year of follow up would be inadequate to detect airway re modelling using this measure. Quality of life did not differ be tween groups. The addition of daily zafirlukast did not dif fer significantly from inter mittent ICS alone in any outcome measured. It may therefore be possible to treat mild persis tent asthma with short, inter mittent courses of inhaled or oral corticosteroids taken when symptoms worsen, but it should be noted that it is debatable whether the primary outcome variable of PEF was the most clinically relevant outcome vari able in such a study.
Natural history of asthma (Prevention of Early Asthma in Kids: PEAK study)
The recommendation to use ICS regularly would be strengthened if this altered the natural history of asthma, especially in children. This was examined in a clinical tri al conducted by the Childhood Asthma Research and Edu cation Network [16] . The asthma predictive index was used to select subjects at high risk of developing asthma. These 285 participants, two or three years of age were then ran domized to treatment with fluticasone propionate (88 μg twice daily) or placebo for 2 years. The primary outcome was the proportion of episode free days during one year of obser for 2 more years. This study differed from the previous studies in a number of respects. It was larger and examined effective ness rather than efficacy. It included significantly milder pa tients and a significantly larger number of children. The dose of ICS used was lower. Most importantly, exacerbations rather than lung function were the primary outcome.
At the end of the 3 years of double blind treatment, 198 of 3568 patients on placebo and 117 of 3597 on budesonide had at least one severe asthma exacerbation; hazard ratio 0.56 (95% CI 0.45-0.71, p <0.0001). Patients on budesonide had fewer courses of systemic corticosteroids and more symptom free days than did those on placebo. Compared with place bo, budesonide increased post bronchodilator forced expirato ry volume in the first second (FEV 1 ) from baseline by 1.48% (p <0.0001) after 1 year and by 0.88% (p = 0.0005) after 3 years (expressed as percent of the predicted value). The effect of treatment was independent of the baseline lung function or baseline medication.
Similar overall benefit was also seen in the 1000 children who received budesonide compared to the 974 children who received placebo [11] . The relative risk of a severe asthma re lated event was reduced by 40% (p = 0.012). Children re ceiving budesonide also needed significantly less inter vention with other ICS (12.3% vs. 22.5% over 3 years; p <0.01), with trends towards decreased usage of systemic corticoster oids and inhaled short acting β 2 agonists.
Treatment with low dose ICS for 3 years was not associ ated with any more adverse effects than observed with pla cebo [12] . Overall, 7221 patients were included in the safe ty analysis, and a total of 21,520 adverse events were report ed (10,850 in the budesonide group and 10,670 in the place bo group). The number of deaths and serious adverse events were similar for children and adults in both groups. Long term treatment with budesonide also appeared to be cost effective, especially in the younger patients [13] .
However, at the end of the 5 year study period, post bronchodilator FEV 1 percent predicted decreased, irrespec tive of assigned treatment during the double blind phase, by an average of 2.22% (SE 0.15%) [14] . There was no sig nificant difference in lung function in either group com pared to the start of the study. This is because, when they received budesonide, the placebo group quickly caught up to the treatment group. The number of exacerbations in this group was also no more frequent than in the patients who re ceived budesonide throughout the study. Hence it would sug gest from this study that there was no significant advantage from starting treatment with budesonide. However, there was greater use of concomitant additional medications in the con trol group. These included ICS other than budesonide, long acting bronchodilators and cromones. It would therefore ap pear that the prescription of ICS can be delayed in some pa tients who may be reluctant to take them without signifi cant deleterious effects as later introduction allows a catch up of lung function. Asthma symptoms could be effectively con trolled to the same degree as patients treated early with ICS vation without the study drug after the 2 year treatment pe riod was complete. Secondary outcomes included exacerba tions, lung function, supplementary use of controller medica tion, and the effect of treatment on growth in height. During the treatment phase, the ICS group had a greater proportion of episode free days, fewer exacerbations, and less use of con troller medications. During the observation phase, however, after treatment was complete, there was no significant differ ence between groups in those outcomes. Growth velocity was reduced in the ICS group during treatment. During the ob servation period, growth velocity in the group that had re ceived ICS was greater than the placebo group, but a 0.7 cm difference in height change remained at the end of the study. Therefore two years of ICS therapy, while improving symp toms during treatment, does not change the incidence of asth ma symptoms after the treatment is stopped.
SUMMARY
Based on this evidence, it is reasonable to draw the follow ing conclusions: In most patients, both adults and children who have a new diagnosis of asthma and whose symptoms are mild but persistent, treatment with ICS should be consid ered. Patients should be cautioned that with short term treat ment their symptoms may recur and lung function may de cline again if treatment is discontinued. Even if treatment is continued regularly, it is unlikely to change the natural histo ry of asthma. If patients are reluctant to use ICS daily for long periods of time, it would be reasonable to offer them inter mittent therapy with ICS if they have mild persistent symp toms. Initial therapy with other antiinflammatory therapies such as leukotriene receptor antagonists are not likely to be as effective as ICS. Since treatment adjustments based on eo sinophil counts in sputum can reliably predict short term re sponses to corticosteroids [17] , it may be useful to use this measurement when available to guide inter mittent therapy.
